Internal Medicine, Medical Oncology · Saint Louis, MO
NPI
1477795607
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4921 Parkview Pl, Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO, 63110
Phone (800) 647-2098
Groups this clinician bills Medicare through
Medicare paid, 2024
$469K
18,794 services
Medicare patients, 2024
368
Average age 73
Drug cost, 2024
$3.5M
1,936 prescriptions
Company payments, 2025
$13K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Neha Mehta-Shah was code 99214 (office e&m - established), 330 times for 153 patients. In total Neha Mehta-Shah billed 18,794 services in 105 codes, and Medicare paid $469K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 330 | 153 | $91.96 | $30K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 280 | 23 | $0.09 | $25.84 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 190 | 15 | $0.76 | $144 |
| 36415 Venipuncture Blood Collection | Office | 141 | 83 | $8.65 | $1,220 |
| 99213 Office E&M - Established | Office | 103 | 86 | $65.01 | $6,696 |
| 99232 Hospital E&M - Subsequent | Facility | 95 | 33 | $60.04 | $5,703 |
| 96413 Chemotherapy Administration | Office | 67 | 54 | $93.72 | $6,279 |
| 99233 Hospital E&M - Subsequent | Facility | 55 | 13 | $90.80 | $4,994 |
| 96375 Injection Administration | Office | 50 | 25 | $11.55 | $578 |
| 99222 Hospital E&M - Initial | Facility | 32 | 32 | $94.89 | $3,036 |
| 99205 Office E&M - New | Office | 24 | 24 | $165.72 | $3,977 |
| 96367 Intravenous Infusion, Hydration | Office | 23 | 19 | $21.26 | $489 |
| 96372 Injection Administration | Office | 23 | 19 | $9.45 | $217 |
| 96402 Chemotherapy Administration | Office | 22 | 19 | $15.73 | $346 |
| 99204 Office E&M - New | Office | 11 | 11 | $104.78 | $1,153 |
By year: 2022 $1.3M for 68,265 services; 2023 $1.4M for 58,156 services; 2024 $469K for 18,794 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 141 | 83 | $8.65 | $1,220 |
Medicare prescription drug claims, 2024
In 2024, the drug Neha Mehta-Shah prescribed most often to Medicare patients was Acyclovir, with 326 prescriptions and refills. In total Neha Mehta-Shah wrote 1,936 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 326 | 415 | 76 | $2,833 |
| Prednisone Generic | 116 | 121 | 53 | $357 |
| Prochlorperazine Maleate Generic | 68 | 68 | 52 | $1,687 |
| Levothyroxine Sodium Generic | 68 | 143 | 16 | $801 |
| Gabapentin Generic | 68 | 121 | 17 | $1,548 |
| Famotidine Generic | 64 | 78 | 11 | $197 |
| Ondansetron Hcl Generic | 56 | 56 | 34 | $300 |
| Triamcinolone Acetonide Generic | 53 | 57 | 23 | $625 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 49 | 60 | 15 | $116 |
| Bexarotene Generic | 37 | 37 | Under 11 | $406K |
| Oxycodone Hcl Generic | 36 | 36 | 14 | $644 |
| Metoprolol Tartrate Generic | 36 | 36 | Under 11 | $79.87 |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $800K |
| Pantoprazole Sodium Generic | 34 | 56 | Under 11 | $193 |
| Escitalopram Oxalate Generic | 32 | 56 | Under 11 | $290 |
Brand drugs: - claims; generic drugs: 1,678 claims; opioid claims: 50.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Neha Mehta-Shah $13K ($8,415 in general payments such as food, travel and fees and $4,453 for research) from 8 companies. The largest payer was Acrotech Biopharma Inc. with $7,926.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.